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Randomized Comparison of Pre-Hospital–Initiated
Facilitated Percutaneous Coronary Intervention
Versus Primary Percutaneous Coronary Intervention
in Acute Myocardial Infarction Very Early After
Symptom Onset
The LIPSIA-STEMI Trial (Leipzig Immediate Prehospital Facilitated Angioplasty in
ST-Segment Myocardial Infarction)
Holger Thiele, MD,* Ingo Eitel, MD,* Claudia Meinberg, BSC,* Steffen Desch, MD,*
nja Leuschner, BSC,* Dietrich Pfeiffer, MD,† Andreas Hartmann, MD,‡ Ulrich Lotze, MD,§
olfgang Strauß, MD, Gerhard Schuler, MD,* for the LIPSIA-STEMI Trial Group
eipzig, Naumburg, and Altenburg, Germany
Objectives This multicenter trial sought to assess the merits of facilitated percutaneous coronary
intervention (PCI) versus primary PCI in an ST-segment elevation myocardial infarction (STEMI) net-
work with long transfer distances in patients presenting early after symptom onset.
Background Facilitated PCI with ﬁbrinolysis might be beneﬁcial in speciﬁc high-risk STEMI situations
to prevent myocardial necrosis expansion.
Methods Patients with STEMI (3 h after symptom onset) were randomized to either pre-hospital–
initiated facilitated PCI using tenecteplase (Group A; n  81) or primary PCI (Group B; n  81) plus
ptimal antithrombotic comedication. The primary endpoint was infarct size assessed by delayed-
nhancement magnetic resonance imaging. Secondary endpoints were microvascular obstruction
nd myocardial salvage, early ST-segment resolution, and a composite of death, repeated myocar-
ial infarctions, and congestive heart failure within 30 days.
esults The median time from symptom onset to randomization was 64 min (interquartile
ange [IQR]: 42 to 103 min) in Group A versus 55 min in Group B (IQR: 27 to 91 min; p  0.26).
espite better pre-interventional TIMI (Thrombolysis In Myocardial Infarction) ﬂow in Group A
71% vs. 35% TIMI ﬂow grade 2 or 3; p  0.001), the infarct size tended to be worse in Group A
versus Group B (17.9% of left ventricle [IQR: 8.4% to 35.0%] vs. 13.7% [IQR: 7.5% to 24.0%]; p  0.10).
There was also a strong trend toward more early and late microvascular obstruction, (p  0.06 and
0.09) and no difference in ST-segment resolution (p  0.26). The combined clinical endpoint
showed a trend toward higher event rates in Group A (19.8% vs. 13.6%; p  0.13, relative risk: 0.52,
95% conﬁdence interval: 0.23 to 1.18).
Conclusions In STEMI patients presenting early after symptom onset with relatively long trans-
fer times, a ﬁbrinolytic-based facilitated PCI approach with optimal antiplatelet comedication
does not offer a beneﬁt over primary PCI with respect to infarct size and tissue perfusion.
([LIPSIA-STEMI] The Leipzig Immediate Prehospital Facilitated Angioplasty in ST-Segment Myo-
cardial Infarction; NCT00359918) (J Am Coll Cardiol Intv 2011;4:605–14) © 2011 by the
American College of Cardiology Foundation
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606The greatest benefits of reperfusion in acute ST-segment
elevation myocardial infarction (STEMI) can be obtained in
the early phase after symptom onset (1,2). In general, pri-
mary percutaneous coronary intervention (PCI) performed in a
timely manner by experienced operators is superior to in-
hospital initiated fibrinolysis for patients presenting to hospi-
tals with and without a cardiac catheterization laboratory (3).
owever, in the early phase (2 to 3 h after symptom onset)
he relative benefit of primary PCI is not as clear cut (4–7).
See page 615
The reduction of total ischemia time by pre-hospital fibrino-
lysis might compensate for the inferiority of fibrinolysis in
achieving TIMI (Thrombolysis In Myocardial Infarction) flow
grade 3 in comparison with primary PCI (8). Current recom-
endations, therefore, require a first-medical-contact-to-
alloon time of 90 min if primary PCI is performed in early
resenters (9,10). However, even in an optimized network of
community hospitals, tertiary re-
ferral centers with 24-h primary
PCI availability, and a technically
advanced ambulance service, in
many patients, these time require-
ments are not met (11). It is only
logical to combine the advantages
of pre-hospital fibrinolysis with
subsequent PCI to achieve opti-
mal results. However, this facili-
tated PCI approach failed to show
any benefit or even caused harm
in comparison with primary PCI
(12–14).
In contrast, high-risk STEMI
subgroups presenting in the early
ourse, those treated in the pre-hospital setting, and those with
onger delays from fibrinolysis to PCI might benefit from
acilitated rather than primary PCI (15–17). In addition,
oncomitant antiplatelet therapy was suboptimal in the facili-
ated PCI arm in some previous trials with late thienopyridine
dministration and no glycoprotein IIb/IIIa inhibitors (12,13).
The aim of this trial was to assess whether facilitated
CI after pre-hospital fibrinolysis with optimized con-
omitant antiplatelet therapy leads to smaller infarct size
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Abbreviations
and Acronyms
ECG  electrocardiogram
IQR  interquartile range
LV  left ventricle
MRI  magnetic resonance
imaging
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial InfarctionvManuscript received December 23, 2010, accepted January 5, 2011.nd better reperfusion and clinical outcomes in compar-
son with primary PCI in STEMI patients presenting
ery early in a regional network with long transfer
istances.
ethods
From August 2006 through August 2009, STEMI patients
with symptoms 3 h were randomized in the ambulance to
pre-hospital fibrinolysis with subsequent direct transfer to
an interventional center for facilitated PCI or transfer for
primary PCI. The trial was conducted in the region of
Leipzig, Germany, covering 19 hospitals without and 3 with
interventional cardiology. (See Appendix for a list of par-
ticipating hospitals and investigators.) The network (Fig. 1)
also consists of 24 mobile intensive care units plus 2
helicopters, all of which are physician-staffed and equipped
with portable electrocardiogram (ECG) recorders that can
transmit the ECG by telemetry. Inclusion criteria were the
presence of ischemic symptoms for 3 h plus ST-segment
elevation 0.1 mV in 2 extremity leads or 0.2 mV in
2 precordial leads. Exclusion criteria were the typical
contraindications to fibrinolysis, such as previous stroke,
active bleeding, history of major trauma or surgery 30
days, active peptic ulcer, neoplasms, uncontrolled hyperten-
sion 200 mm Hg, chronic oral anticoagulation, cardio-
genic shock, and pregnancy. Additional exclusion criteria
were typical contraindications for magnetic resonance im-
aging (MRI) at randomization, such as pacemakers, defi-
brillators, and intracerebral metallic clips.
The study was approved by the local ethics committees,
and all patients gave written informed consent.
Study protocol. After diagnosis by the emergency physician,
ontact was made with the study coordinating center that
andomized the patients by drawing sealed envelopes to 1 of
he treatment arms: pre-hospital facilitated PCI (Group A)
r primary PCI (Group B). All patients received 500 mg of
spirin and heparin (60 U/kg, maximum 5,000 U) intrave-
ously plus 600 mg of clopidogrel orally. In patients as-
igned to the facilitated PCI arm, this medication was
ollowed by a weight-adjusted dose of intravenous tenect-
plase, as described previously (12).
Patients in both groups were transported immediately to
of 3 hospitals with catheterization laboratories after tele-
hone announcement, bypassing any emergency depart-
ent. The aim was to optimize the time-to-first-balloon
nflation. The achieved door-to-balloon times for the indi-
idual patients were published online on the next day to
llow direct feedback between hospital and ambulance staff.
PCI was performed according to local standards in case of
totally occluded infarct-related artery, culprit lesion ste-
osis of 50%, and/or a reduced TIMI flow grade 3.
tenting of the culprit lesion was recommended unless the
essel had a diameter of2.0 mm. The use of bare-metal or
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607drug-eluting stents and thrombectomy was left to the
interventionalist’s discretion. After PCI, the sheath was
removed and the puncture site treated by a closure device or
using a compression system until hemostasis.
The use of glycoprotein IIb/IIIa inhibitors was recom-
mended at standard dose for 12 h in both groups, in
particular, in patients with high thrombus burden and
reduced TIMI flow grade after PCI. During PCI, addi-
tional heparin doses were given adjusted to the activated
clotting time (target: 200 to 250 s).
In both study groups, there was no continuous heparin
infusion after hospital arrival. Clopidogrel at 75 mg/day was
recommended for 12 months.
The following times were recorded: initial onset of
angina, arrival on scene of the emergency physician, first
12-lead ECG, injection of the tenecteplase bolus, hospital
arrival, first balloon inflation, and post-PCI ECG.
Angiographic analysis. The initial and final TIMI flow
grades of the culprit vessel were assessed offline in the
angiographic core laboratory by 2 blinded observers with
averaging of the TIMI flow grades in cases of disagreement.
ST-segment resolution. For ECG interpretation, blinded
observers measured the sum of ST-segment elevation 20 ms
after the end of the QRS complex in the initial pre-hospital
ECG and that obtained early after PCI directly after
transfer to the intensive care unit. By protocol, no additional
Figure 1. The LIPSIA-STEMI Network
Locations of the 24 mobile intensive care units (most of them with afﬁliate
dot, and the 3 catheterization laboratories with blue crosses. LIPSIA-STEM
cardial Infarction.ECG was obtained immediately before cardiac catheteriza-tion to optimize door-to-balloon times. ST-segment reso-
lution was calculated as the sum of ST-segment elevation
before minus the sum of ST-segment elevation after PCI
divided by the sum of ST-segment elevation before PCI.
ST-segment resolution was expressed as a percentage, as
described previously (18).
Magnetic resonance imaging. Myocardial infarct size, mi-
rovascular obstruction, and myocardial salvage were ac-
uired on clinical 1.5-T scanners from different vendors
Philips, Best, the Netherlands; and Siemens, Erlangen,
ermany) using the same acquisition protocol as described
reviously (18). Left ventricular (LV) function was assessed
y a steady-state free precession technique. For area-at-risk
etermination, short-axis slices covering the whole ventricle
sing a T2-weighted turbo spin-echo sequence were ob-
tained. Early and delayed enhancement images covering the
whole ventricle were acquired approximately 1 and 15 min
after intravenous administration of 0.2 mmol/kg body
weight of gadolinium chelate. Total LV mass, early and late
microvascular obstruction, area at risk, and infarct size were
assessed manually from these images by fully blinded oper-
ators at the MRI core laboratory (18). The following
parameters were calculated: 1) area at risk  volume
edema/volume LV mass  100; 2) percent infarct size 
volume infarct/volume LV mass  100; 3) percentage of
microvascular obstruction  volume microvascular obstruc-
pitals) are displayed with red dots, location of helicopters with green
ipzig Immediate Prehospital Facilitated Angioplasty in ST-Segment Myo-d hos
I  Letion/volume LV mass  100; 4) myocardial salvage  area
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608at risk-infarct size; and 5) myocardial salvage index  (area
t risk-infarct size)/area at risk.
The MRI core laboratory has excellent reproducibility
nd interobserver and intraobserver variability for infarct
ize measurement (19).
Infarct size measured by enzyme release. Infarct size was
lso assessed indirectly by the area under the curve of
reatine kinase-myocardial band release derived from mea-
urements every 6 h over 48 h.
Clinical endpoints. Clinical endpoints were a composite of
death, reinfarction, and the occurrence of new congestive
heart failure 30 days after randomization. For post-
hospital follow-up each patient had a 30-day outpatient
visit. The diagnosis of reinfarction was based on previous
definitions (18). New heart failure was defined as any
congestive heart failure (rales, dyspnea, New York Heart
Association functional class III to IV) occurring24 h after
the index event. Outcomes were adjudicated by a clinical
events committee blinded to the patients’ assigned
treatments.
Safety. Major safety endpoints were severe or life-
hreatening, moderate, or minor bleeding as assessed by the
USTO (Global Use of Strategies to Open Occluded
oronary Arteries) trial (20) and the occurrence of any
schemic stroke.
Statistical analysis. The number of patients included was
based on the sample size estimation for the primary study
endpoint, infarct size. Based on a previous study comparing
pre-hospital initiated facilitated PCI versus pre-hospital
fibrinolysis with standard care and previous primary PCI
trials (21–23), we assumed that the final infarct size would
be 7 6% after facilitated PCI and 12 10% after primary
PCI. With a power of 80% and a 2-sided alpha value of
0.05, we estimated that 64 patients would be required in
each group. Based on previous trials, we expected that not
all patients would undergo MRI for primary endpoint
assessment and, therefore, included 162 patients. A pre-
defined subgroup analysis was performed for anterior/
nonanterior STEMI, and different times from symptom
onset to randomization (1 h, 1 to 2 h, and 2 h). With
the exception that patients with nonconfirmed STEMI at
inclusion were excluded, all analyses were performed ac-
cording to the intention-to-treat principle.
Categorical data are presented as counts or proportions
with the corresponding percentages. Most continuous
variables had non-normal distribution (as evaluated by
Kolmogorov-Smirnov test). For reasons of uniformity, sum-
mary statistics for all continuous variables are therefore
presented as medians with interquartile range (IQR).
Differences between the treatment groups were assessed
by Fisher exact or the chi-square tests for categorical
variables and by the Student t test for continuous data with
normal distribution. Otherwise, the nonparametric Wil-
coxon rank sum test was used. For the combined secondaryclinical endpoint, the Kaplan-Meier method was applied,
and differences were assessed by the log-rank test.
A multivariable linear-regression model including age,
sex, diabetes, hypertension, symptom duration-random-
ization, infarct location, pre- and post-interventional TIMI
flow grade, and glycoprotein IIb/IIIa inhibitor use was
applied to assess confounders for infarct size. All statistical
tests were performed with SPSS software (version 17.0,
IBM, Armonk, New York). A 2-tailed p value 0.05 was
considered statistically significant.
Results
Of the 162 patients enrolled, 81 were randomly assigned to
pre-hospital facilitated PCI and 81 to primary PCI (Fig. 2).
All patients received the assigned pre-hospital therapy.
Most patients were included in the rural setting (72.3%),
and the median transport distance for all patients was 42 km
(IQR: 21 to 53 km). Baseline characteristics were similar
between the 2 treatment groups (Table 1). Altogether, 4
patients (2.5%) had to be excluded from further analysis for
misdiagnosis of STEMI (pericarditis, n  1; ECG misin-
terpretation, n  2; apical ballooning syndrome, n  1).
heir clinical course was otherwise uneventful.
Reperfusion. The different time-steps from symptom onset
to reperfusion are shown in Figure 3. Due to slightly longer
symptom arrival times of the mobile intensive care unit and
due to longer treatment and transportation times in the
facilitated PCI group, the overall symptom-onset-to-first-
balloon-inflation times were longer (158 min, IQR: 119 to
222 vs. 131 min, IQR: 106 to 175 min; p  0.01), although
the door-to-balloon times were extremely short in both
groups with 23 min (IQR: 20 to 31 min) versus 25 min
(IQR: 18 to 34 min; p  0.75).
All patients assigned to facilitated PCI underwent diag-
nostic angiography, and there were 74 (92.5%) facilitated
PCI procedures (death before PCI, n  1; no angiographi-
cally significant stenosis, n  3; coronary artery bypass
grafting several days after the index event, n  1; small
peripheral vessel, n  1). In the primary PCI group, all
patients underwent diagnostic angiography, and PCI was
not performed in 2 patients (coronary artery bypass grafting,
n  1; no relevant stenosis after spontaneous lysis, n  1).
mmediately before PCI, there were TIMI flow grades 2
nd 3 in 26.6% and 44.3% of the facilitated PCI group and
0.3% and 24.4% of the primary PCI group (p  0.001).
ost-stenting, TIMI flow grade 3 in the infarct-related
rtery was present in 83.2% versus 88.5% (p  0.44).
Magnetic resonance imaging. Complete MRI results were
available in 69 patients (86.3%) of the pre-hospital facili-
tated PCI group and in 71 (91.0%) of the primary PCI
group (Table 2). Reasons for missing data are shown in
Figure 2. MRI was performed at day 3 (IQR: 2 to 4 days)
in both groups (p  0.44). Patients in both groups had
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609similar areas at risk. The primary endpoint, infarct size,
tended to be higher in the facilitated PCI group (p  0.10),
nd there was also a strong trend toward a greater extent of
arly and late microvascular obstruction in the facilitated
CI group (p  0.06 and 0.09, respectively).
There were no significant differences in the correspond-
ng myocardial salvage, myocardial salvage index, or LV
unction and volumes.
The primary endpoint was also analyzed in several pre-
efined subgroups. These results show the consistency of
RI among the subgroups (Figs. 4A and 4B).
In a multivariable linear regression model, the strongest
redictors for increasing infarct size were post-PCI TIMI
ow grade, symptom duration, and anterior infarct location
p  0.01 for all). The reperfusion type and glycoprotein
Ib/IIIa inhibitor use had no effect on infarct size (p  0.21
nd 0.34). There was also no difference in the primary
ndpoint with respect to transportation distances and pre-
CI TIMI flow grade.
Infarct size measured by enzyme release. The infarct size
assessed by the area under the curve of creatine kinase-
myocardial band release was higher in the facilitated PCI in
comparison with the primary PCI group (67.9 mol/l/h,
IQR: 44.0 to 94.8 mol/l/h vs. 48.5 mol/l/h, IQR: 26.8 to
83.7 mol/l/h; p  0.02).
ST-segment resolution. The number of leads with ST-
Figure 2. Trial Profile
Trial proﬁle showing the number of patients screened, excluded, and evaluate
sons for exclusion are shown. MRI  magnetic resonance imaging; PCI  percsegment elevation in the pre-hospital setting was 5.0 (IQR:4.0 to 6.0) in the facilitated PCI and 5.0 (IQR: 4.0 to 5.5)
in the primary PCI group (p 0.27). Similarly, the absolute
ST-segment elevation was 1.2 mV (IQR: 0.8 to 1.9 mV)
versus 1.1 mV (IQR: 0.7 to 1.7 mV; p 0.20). The median
ime between the pre-hospital ECG and the post-PCI
CG was similar between both treatment groups (pre-
ospital facilitated PCI: 120 min, IQR: 99 to 143 min;
rimary PCI: 113 min, IQR: 93 to 136 min; p  0.14).
T-segment resolution as a continuous variable was similar
n the facilitated PCI in comparison with the primary PCI
roup (66.7, IQR: 44.5 to 92.9 vs. 75.0, IQR: 50.0 to 100.0;
 0.26). Accordingly, the percentage of patients with
omplete (42.9% vs. 57.7%), intermediate (40.2% vs.
9.5%), and no ST-segment recovery (16.9% vs. 12.8%) was
imilar in both groups (p  0.18).
Clinical endpoints. At 30-day follow-up, 5 patients (6.1%)
died in the pre-hospital facilitated PCI and 4 (4.9%) in the
primary PCI group. Nonfatal reinfarctions occurred in 5
patients (6.1%) after pre-hospital facilitated PCI and in 4
(4.9%) after primary PCI. Additionally, there were 6 (7.4%)
versus 3 (3.7%) patients with new congestive heart failure.
The composite secondary endpoint of death, reinfarction,
and new congestive heart failure was reached in 16 patients
(19.8%) after pre-hospital facilitated PCI and in 11 (13.6%)
after primary PCI (relative risk: 0.52, 95% confidence
he primary endpoint and for the clinical endpoint with follow-up. The rea-
ous coronary intervention.d for tinterval: 0.23 to 1.18, p  0.13).
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610Safety. There were no differences in bleeding according to
he GUSTO severity criteria in the 2 treatment groups
severe/life-threatening: 2.5% vs. 2.5%, moderate: 2.5% vs.
.7%, mild: 4.9% vs. 7.4%; p  NS for all). In addition,
here was 1 ischemic stroke in each group.
iscussion
In line with previous studies comparing facilitated PCI versus
primary PCI, there was no benefit of facilitated PCI over
primary PCI even in patients presenting very early after
symptom onset in the pre-hospital setting with relatively long
transfer distances to a cardiac catheterization laboratory.
The trend toward greater infarct sizes on MRI in the
facilitated PCI group (significant with enzyme measure-
ments) seems paradoxical at first glance. Patients in the
facilitated PCI group in the current trial displayed higher
TIMI flow grade 3 before PCI, indicating earlier reperfu-
sion in comparison with primary PCI patients. From a
conventional point of view, this should result in smaller
infarct size and greater myocardial salvage in the facilitated
Table 1. Main Patient Characteristics
Variable
Pre-Hospit
(
Age, yrs 63
Male 61
Cardiovascular risk factors
Current smoking 33
Hypertension 53
Hypercholesterolemia 32
Diabetes mellitus 29
Prior myocardial infarction 2
Prior coronary artery bypass grafting
Anterior myocardial infarction 34
Systolic blood pressure, mm Hg 130
Diastolic blood pressure, mm Hg 80
Heart rate, beats/min 83
Killip class on admission
1 57
2 11
3 5
4 7
Concomitant medications
Beta-blockers 77
ACE inhibitors/AT1 antagonists 78
Aspirin 79
Clopidogrel 80
Statins 78
Aldosterone antagonists 5
Glycoprotein IIb/IIIa inhibitors 23
Values are median (interquartile range) or n (%).
ACE angiotensin-converting enzyme; AT1 angiotensin 1; PCIPCI group. In fact, a previous large trial using PCIfacilitation with half-dose reteplase and abciximab showed
improved TIMI flow grades before facilitated PCI with
subsequent decrease in the area under the curve for creatine
kinase compared with primary PCI, implying greater myo-
cardial salvage (13). In the current study, however, a trend in
the opposite direction was seen. Several hypotheses might
explain these findings. First, a typical criticism of pre-
hospital fibrinolysis is the additional time delay required for
administration of the lytic agent rather than starting imme-
diate hospital transfer. Previous trials have shown that
pre-hospital fibrinolysis requires approximately 7 to 15
additional minutes before the start of transport to the
hospital, eventually resulting in longer symptom-onset-to-
balloon times as compared to patients undergoing primary
PCI (5,24). In the current trial, the difference in symptom-
onset-to-balloon times between groups was 20 min in
median, presumably caused by the preparation and applica-
tion of the fibrinolytic bolus. This delay might be especially
relevant in patients not achieving adequate TIMI flow grade
by fibrinolysis alone. The benefit of a higher infarct artery
patency rate upon initial angiography in the facilitated PCI
ilitated PCI
0)
Primary PCI
(n  78) p Value
3) 61 (53–72) 0.57
64 (82) 0.48
38 (48) 0.43
50 (64) 0.91
21 (26) 0.12
19 (24) 0.15
4 (5) 0.65
1 (1) 0.99
38 (51) 0.39
143) 133 (114–146) 0.51
6) 79 (67–87) 0.93
3) 77 (70–85) 0.18
0.36
58 (74)
14 (18)
4 (5)
2 (3)
77 (99) 0.63
76 (97) 0.63
78 (100) 0.99
78 (100) 1.00
76 (97) 0.63
3 (4) 0.74
71 (88) 0.001
aneous coronary intervention.al Fac
n  8
(54–7
(76)
(41)
(66)
(40)
(36)
(3)
0
(43)
(112–
(70–8
(69–9
(71)
(14)
(6)
(9)
(96)
(98)
(99)
(100)
(98)
(6)
(29)group might have been offset by the delay in mechanical
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611treatment of the infarct-related artery. This might be
especially relevant in STEMI patients presenting very early
after symptom onset, as supported by recent MRI data
demonstrating a progressive decrease of the salvaged area at
risk (while infarct size and microvascular obstruction in-
crease) when reperfusion occurs 90 min of coronary
Figure 3. Key Median Treatment Intervals
The key median treatment intervals for facilitated PCI (A) and primary PCI (B).
MICU  mobile intensive care unit.
Table 2. MRI Results
Variable
Pre-Hospital Faci
(n  69
LV ejection fraction, % 57.4 (49.7–6
LV end-diastolic volume, ml 125.1 (100.9–
LV end-systolic volume, ml 55.5 (33.8–7
Area at risk 33.1 (24.4–4
Infarct size, % LV 17.9 (8.4–35
Early MO, % LV 3.4 (1.0–7.9
Late MO, % LV 1.3 (0.5–6.1
Myocardial salvage, % LV 13.5 (5.1–23
Myocardial salvage index 42.9 (27.0–6
Values are median (interquartile range).LV left ventricle; MOmicrovascular obstruction; PCI percutaneous cocclusion (1). There seems to be a “golden window” during
which even small delays in reperfusion time are highly
clinically relevant. Second, the trend toward greater infarct
size and microvascular obstruction in the facilitated PCI
group might also be attributed to paradoxical fibrinolytic-
induced platelet aggregation and thrombin-induced platelet
door-to-balloon time; ECG  electrocardiogram; IQR  interquartile range;
PCI Primary PCI
(n  70) p Value
60.3 (51.5–67.0) 0.72
115.4 (104.2–140.0) 0.31
47.3 (35.4–63.8) 0.47
32.2 (19.9–41.1) 0.34
13.7 (7.5–24.0) 0.10
1.9 (0.0–5.9) 0.06
0.9 (0.0–3.9) 0.09
15.3 (9.1–21.6) 0.35
48.9 (33.7–68.5) 0.11D2B litated
)
6.9)
153.9)
2.3)
8.7)
.0)
)
)
.7)
6.9)oronary intervention.
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612activation, despite the early and concomitant use of clopi-
dogrel (25). A different pharmacological regimen such
as half-dose fibrinolytics in conjunction with glycoprotein
IIb/IIIa inhibitors might be more beneficial in this situa-
tion’s results (16). Third, early reperfusion of the infarct-
related artery may not reflect tissue-level myocardial reper-
fusion and TIMI flow grade 3, therefore, does not guarantee
effective myocardial perfusion (26). Fourth, another signif-
icant difference between study groups was the lower use of
glycoprotein IIb/IIIa inhibitors in the facilitated PCI group,
which was likely influenced by investigator decisions and the
fear of bleeding complications with a combined full-dose
fibrinolytic drug. Of note, its use was significantly higher in
comparison with a previous trial because glycoprotein IIb/
Figure 4. Subgroup Analysis
Subgroup analysis for the comparison of facilitated percutaneous coronary
intervention (PCI) (red boxes) versus primary PCI (white boxes) for ante-
rior and nonanterior infarction (A) and different times from symptom onset
to randomization (B). Boxes indicate 25th percentile, median, and 75th
percentile; whiskers indicate the 10th and 90th percentiles. Dots indicate
outliers.IIIa inhibitors were not restricted to bailout indications (12).Despite the concomitant antiplatelet therapy, no higher bleed-
ing complications or stroke were noted. Fifth, the actual delays
from medical contact to balloon inflation were still quite short
because of the optimized network. It may be that facilitated
PCI has advantages over primary PCI only in patients with
much longer delays to PCI. Finally, despite having included a
relative high-risk population characterized by the relatively
high event rates in both groups and the number of affected
leads in the ECG, only extreme high-risk patients might
benefit from facilitated PCI.
Infarct size as an endpoint in reperfusion trials has been
advocated because of its prognostic value (23). MRI is
considered the reference method, and it has also the
advantage to allow the assessment of microvascular obstruc-
tion with its additional independent prognostic impact
(27,28). Moreover, we also used state-of-the-art techniques
to assess the area at risk and also the salvaged myocardium,
excluding any baseline differences between the treatment
groups (1,18).
The current study is in line with several large-scale trials
showing that a facilitated approach as compared to primary
PCI causes harm or is neutral at best (12–14). However, this
is in contrast to trials comparing facilitated PCI versus
fibrinolysis only (29). Given the current evidence, more
efforts should be directed to establish well-functioning net-
works with short door-to-balloon times to deliver primary
PCI to most patients (23). Although nearly 80% of the adult
population lives within a 1-h drive of a PCI center in the
United States and also in many European countries (30), the
full benefits of primary PCI still cannot be offered to most
of these patients (11). The door-to-balloon times in the
current trial were much shorter than those reported from
other studies and registries with door-to-balloon times of 87
to 108 min (31). This clearly demonstrates the ability to
meet current first-medical-contact-to-balloon time require-
ments even for patients in rural settings (10). To achieve
these extremely short first-medical-contact and also door-
to-balloon times, a dedicated network of mobile intensive
care units and helicopters with direct access to a catheter-
ization laboratory as well as pre-announcement by the am-
bulance service are required.
Study limitations. The most important limitation is the
open-label design that led to a lower use of glycoprotein
IIb/IIIa inhibitors in the facilitated PCI group. However,
multivariable adjustment did not show an influence of gly-
coprotein IIb/IIIa inhibitor use. MRI, angiographic, labo-
ratory, and ECG results were assessed by blinded observers,
and stringent definitions for reporting were provided, lim-
iting the influence of the open-label design. Another limi-
tation is that this trial had sufficient statistical power only to
assess final infarct size—this precludes meaningful interpre-
tation of the combined clinical endpoint—and some pa-
tients were not assessed for the primary study endpoint due
to contraindications. The exclusion of patients from MRI is
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613inherent to this imaging method. However, the percentage
of patients excluded from MRI was similar to previous
trials, and this was taken into account by the a priori sample
size calculation (21,23). Moreover, these patients were in-
cluded in the enzymatic infarct size, ST-segment resolution,
and clinical adverse events analysis.
Conclusions
In an optimized STEMI network, pre-hospital initiated
facilitated PCI does not add a benefit over primary PCI
with respect to infarct size in STEMI patients presenting
very early after symptom onset despite an earlier angio-
graphic reperfusion and optimal antithrombotic comedica-
tion. These results based on a surrogate endpoint do not
support proceeding to a large-scale clinical trial of facilitated
PCI in this selected patient group. However, facilitated PCI
could still prove beneficial in patients with longer delays to
PCI.
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